These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
262 related articles for article (PubMed ID: 38453446)
1. [Progress on Neoadjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer]. Qi C; Tian P; Li W Zhongguo Fei Ai Za Zhi; 2024 Feb; 27(2):138-146. PubMed ID: 38453446 [TBL] [Abstract][Full Text] [Related]
2. Advances in clinical trials on perioperative immune checkpoint inhibitors for resectable non-small cell lung cancer: A comprehensive review. Cui S; Wang N; Liang Y; Meng Y; Shu X; Kong F Int Immunopharmacol; 2024 Nov; 141():112903. PubMed ID: 39146783 [TBL] [Abstract][Full Text] [Related]
4. Current status and future perspectives on immunotherapy in neoadjuvant therapy of resectable non-small cell lung cancer. Liu X; Xing H; Liu H; Chen J Asia Pac J Clin Oncol; 2022 Aug; 18(4):335-343. PubMed ID: 34811893 [TBL] [Abstract][Full Text] [Related]
5. The Emerging Role of Immunotherapy in Resectable Non-Small Cell Lung Cancer. Dunne EG; Fick CN; Isbell JM; Chaft JE; Altorki N; Park BJ; Spicer J; Forde PM; Gomez D; Iyengar P; Harpole DH; Stinchcombe TE; Liberman M; Bott MJ; Adusumilli PS; Huang J; Rocco G; Jones DR Ann Thorac Surg; 2024 Jul; 118(1):119-129. PubMed ID: 38316378 [TBL] [Abstract][Full Text] [Related]
8. [Biomarkers for Neoadjuvant Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer]. Shu C; Zhu D; Zhou Q Zhongguo Fei Ai Za Zhi; 2022 Feb; 25(2):130-136. PubMed ID: 35224967 [TBL] [Abstract][Full Text] [Related]
9. Current Approaches to Neoadjuvant Immunotherapy in Resectable Non-small Cell Lung Cancer. Parekh J; Parikh K; Reuss JE; Friedlaender A; Addeo A Curr Oncol Rep; 2023 Aug; 25(8):913-922. PubMed ID: 37249833 [TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant immunotherapy for non-small cell lung cancer: State of the art. Kang J; Zhang C; Zhong WZ Cancer Commun (Lond); 2021 Apr; 41(4):287-302. PubMed ID: 33689225 [TBL] [Abstract][Full Text] [Related]
11. Immunotherapy in Early-Stage Non-Small Cell Lung Cancer (NSCLC): Current Evidence and Perspectives. Lazzari C; Spagnolo CC; Ciappina G; Di Pietro M; Squeri A; Passalacqua MI; Marchesi S; Gregorc V; Santarpia M Curr Oncol; 2023 Mar; 30(4):3684-3696. PubMed ID: 37185393 [TBL] [Abstract][Full Text] [Related]
12. Surgical Perspective on Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer. Lee JM; Tsuboi M; Brunelli A Ann Thorac Surg; 2022 Oct; 114(4):1505-1515. PubMed ID: 34339672 [TBL] [Abstract][Full Text] [Related]
13. Clinical recommendations for perioperative immunotherapy-induced adverse events in patients with non-small cell lung cancer. Ni J; Huang M; Zhang L; Wu N; Bai CX; Chen LA; Liang J; Liu Q; Wang J; Wu YL; Zhang FC; Zhang SY; Chen C; Chen J; Fang WT; Gao SG; Hu J; Jiang T; Li SQ; Li HC; Liao YD; Liu Y; Liu DR; Liu HX; Liu JY; Liu LX; Wang MZ; Wang CL; Yang F; Yang Y; Zhang LJ; Zhi XY; Zhong WZ; Guan YZ; Guo XX; He CX; Li SL; Li Y; Liang NX; Lu FL; Lv C; Lv W; Si XY; Tan FW; Wang HP; Wang JS; Yan S; Yang HX; Zhu HJ; Zhuang JL; Zhuo ML Thorac Cancer; 2021 May; 12(9):1469-1488. PubMed ID: 33787090 [TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant Immunotherapy for NSCLC: Current Concepts and Future Approaches. Uprety D; Mandrekar SJ; Wigle D; Roden AC; Adjei AA J Thorac Oncol; 2020 Aug; 15(8):1281-1297. PubMed ID: 32522713 [TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant-Adjuvant vs Neoadjuvant-Only PD-1 and PD-L1 Inhibitors for Patients With Resectable NSCLC: An Indirect Meta-Analysis. Zhou Y; Li A; Yu H; Wang Y; Zhang X; Qiu H; Du W; Luo L; Fu S; Zhang L; Hong S JAMA Netw Open; 2024 Mar; 7(3):e241285. PubMed ID: 38451524 [TBL] [Abstract][Full Text] [Related]
16. [Research Progress, Benefit Groups, Treatment Cycle and Efficacy Prediction of Neoadjuvant Immunotherapy for Non-small Cell Lung Cancer]. Ji J; Zhang C; Peng L; Jiao W Zhongguo Fei Ai Za Zhi; 2022 Feb; 25(2):92-101. PubMed ID: 35224962 [TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant SBRT combined with immunotherapy in NSCLC: from mechanisms to therapy. Shi Y; Ma X; He D; Dong B; Qiao T Front Immunol; 2023; 14():1213222. PubMed ID: 37600799 [TBL] [Abstract][Full Text] [Related]
18. Safety and Efficacy of Neoadjuvant Immune Checkpoint Inhibitor Therapy in Patients with Resectable Non-small-Cell Lung Cancer: A Systematic Review. Zhao Z; Gao Y; Xue Q; Gao S; He J Target Oncol; 2021 Jul; 16(4):425-434. PubMed ID: 33983556 [TBL] [Abstract][Full Text] [Related]
19. [Progress of immune checkpoint inhibitors in neoadjuvant therapy of non-small cell lung cancer]. Chen XY; Yang F Zhonghua Wai Ke Za Zhi; 2019 Nov; 57(11):872-877. PubMed ID: 31694138 [TBL] [Abstract][Full Text] [Related]
20. [Progress in Neoadjuvant Immunotherapies for Resectable Non-small Cell Lung Cancer]. Wang S; Mao Y Zhongguo Fei Ai Za Zhi; 2020 May; 23(5):371-380. PubMed ID: 32283581 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]